Makary resigns, with Diamantas named as acting FDA commissioner
Following news that started brewing last week, Dr Marty Makary has officially resigned from his post as commissioner of the …
Post
-
-
BMS and Hengrui forge $15.2bn alliance for early-stage drugs
Bristol Myers Squibb (BMS) and Chinese biopharma company Hengrui Pharma have inked one of the largest licensing and collaboration deals …
-
FDA weighs drug repurposing pathway for underserved diseases
The US Food and Drug Administration (FDA) is considering a new framework that could allow approved medicines to be repurposed …
-
Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities
Manufacturing deals saw an unusual burst of activity recently, with a spike in the number of contract development and manufacturing …
-
BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial
BridgeBio has revealed new pivotal trial data for Attruby (acoramidis) along with results from an indirect comparison to Pfizer’s Vyndamax …
-
BMS and Hengrui forge $15.2bn alliance for early-stage drugs
Bristol Myers Squibb (BMS) and Chinese biopharma company Hengrui Pharma have inked one of the largest licensing and collaboration deals …
-
FDA weighs drug repurposing pathway for underserved diseases
The US Food and Drug Administration (FDA) is considering a new framework that could allow approved medicines to be repurposed …
-
Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities
Manufacturing deals saw an unusual burst of activity recently, with a spike in the number of contract development and manufacturing …
-
BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial
BridgeBio has revealed new pivotal trial data for Attruby (acoramidis) along with results from an indirect comparison to Pfizer’s Vyndamax …
-
GSK and SBP Group team up to advance bepirovirsen launch in China
GSK has entered an exclusive strategic partnership with SBP Group, via its subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), to …
-
Partner Therapeutics secures FDA approval for Bizengri
Partner Therapeutics has received the US Food and Drug Administration (FDA) approval for Bizengri (zenocutuzumab-zbco) to treat adults with advanced, …
-
Cellular Intelligence licenses Novo’s shelved Parkinson’s cell therapy programme
Cellular Intelligence has licensed Novo Nordisk’s cell therapy programme for Parkinson’s disease, seven months after the Danish drugmaker wound down …
-
FDA locks down post-approval pregnancy safety data framework
The US Food and Drug Administration (FDA) has debuted its final industry guidance on collecting post-marketing safety data for both …
-
ACROBiosystems upgrades HEK293 licence solution for R&D compliance
ACROBiosystems has upgraded its global licence solution for HEK293 functional cell lines, aimed at streamlining compliance to expedite biopharmaceutical research …
-
BMS’ Sotyktu secures EC approval for psoriatic arthritis
Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for Sotyktu (deucravacitinib) to treat active psoriatic arthritis …
